Screener
CRISPR Therapeutics CRSP Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Financing activities: | ||
| Proceeds from issuance of the Notes | 600,000 | — |
| Issuance costs and discounts associated with the Notes | (13,528) | — |
| (Payments) proceeds from issuance of common shares, net of issuance costs | (722) | 8,516 |
| Proceeds from exercise of options and ESPP contributions, net of issuance costs | 6,158 | 2,072 |
| Net cash provided by financing activities | 591,908 | 10,588 |
| Effect of exchange rate changes on cash | (32) | 41 |
| Increase (decrease) in cash | 72,236 | (63,073) |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's stock issuance proceeds?
- CRISPR Therapeutics (CRSP) reported stock issuance proceeds of -$722K in Q1 2026.
- How has CRISPR Therapeutics's stock issuance proceeds changed year-over-year?
- CRISPR Therapeutics's stock issuance proceeds decreased by 108.5% year-over-year, from $8.52M to -$722K.
- What is the long-term trend for CRISPR Therapeutics's stock issuance proceeds?
- Over 3 years (2022 to 2025), CRISPR Therapeutics's stock issuance proceeds has grown at a 643.2% compound annual growth rate (CAGR), from $970K to $398.11M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.
Ask your AI about CRISPR Therapeutics's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude